Evaluation of host-based molecular markers for the early detection of human sepsis.


Journal

Journal of biotechnology
ISSN: 1873-4863
Titre abrégé: J Biotechnol
Pays: Netherlands
ID NLM: 8411927

Informations de publication

Date de publication:
20 Feb 2020
Historique:
received: 25 07 2019
revised: 18 01 2020
accepted: 27 01 2020
pubmed: 6 2 2020
medline: 8 10 2020
entrez: 5 2 2020
Statut: ppublish

Résumé

We have identified 24 molecular markers, based on circulating nucleic acids (CNA) originating from the human genome, which in combination can be used in a quantitative real-time PCR (qPCR) assay to identify the presence of human sepsis, starting two to three days before the first clinical signs develop and including patients who meet the SEPSIS-3 criteria. The accuracy was more than 87 % inside of the same patient cohort for which the markers were developed and up to 81 % in blind studies of patient cohorts which were not included in the marker development. As our markers are host-based, they can be used to capture bacterial as well as fungal sepsis, unlike the current PCR-based tests, which require species-specific primer sets for each organism causing human sepsis. Our assay directly uses an aliquot of cell-free blood as the substrate for the PCR reaction, thus allowing to obtain the diagnostic results in three to four hours after the collection of the blood samples.

Identifiants

pubmed: 32017954
pii: S0168-1656(20)30015-8
doi: 10.1016/j.jbiotec.2020.01.013
pii:
doi:

Substances chimiques

Biomarkers 0
DNA, Bacterial 0
DNA, Fungal 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

80-88

Subventions

Organisme : Austrian Science Fund FWF
ID : KLI 561
Pays : Austria

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest None.

Auteurs

Elisabeth Ullrich (E)

Institute of Hygiene, Microbiology and Environmental Medicine, Medical University of Graz, Neue Stiftingtalstraße 6, 8010, Graz, Austria.

Petra Heidinger (P)

acib GmbH, Petersgasse 14, 8010, Graz, Styria, Austria.

Jung Soh (J)

CNA Diagnostics Inc., Suite 300, 4838 Richard Road SW, Calgary, Alberta, T3E 6L1, Canada.

Laura Villanova (L)

Institute of Computational Biotechnology, Graz University of Technology, Petersgasse 14/V, 8010, Graz, Styria, Austria.

Stefan Grabuschnig (S)

Institute of Computational Biotechnology, Graz University of Technology, Petersgasse 14/V, 8010, Graz, Styria, Austria.

Thorsten Bachler (T)

acib GmbH, Petersgasse 14, 8010, Graz, Styria, Austria.

Elisabeth Hirschböck (E)

CNA Diagnostics GmbH, Parkring 18, 8074, Grambach, Styria, Austria.

Sara Sánchez-Heredero (S)

Institute of Computational Biotechnology, Graz University of Technology, Petersgasse 14/V, 8010, Graz, Styria, Austria.

Barry Ford (B)

Defence Research and Development Canada, Suffield Research Centre, Suffield, P.O. box 4000 Stn Main, T1A 8K6, Medicine Hat, Alberta, Canada.

Maria Sensen (M)

Hochstraße 12, 8076, Vasoldsberg, Styria, Austria.

Ingund Rosales Rodriguez (I)

CNA Diagnostics GmbH, Parkring 18, 8074, Grambach, Styria, Austria.

Daniel Schwendenwein (D)

acib GmbH, Petersgasse 14, 8010, Graz, Styria, Austria.

Peter Neumeister (P)

Clinical Division for Hematology, Medical University of Graz, Auenbruggerplatz 38D, 8036 Graz, Styria, Austria.

Christoph J Zurl (CJ)

Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Auenbruggerplatz 34/II, 8036, Graz, Styria, Austria.

Robert Krause (R)

Section of Infectious Diseases and Tropical Medicine, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Styria, Austria; BioTechMed Graz, Mozartgasse 12/II, 8010, Graz, Styria, Austria.

Johannes Lorenz Khol (J)

Department for Farm Animals and Veterinary Public Health, University Clinic for Ruminants, University of Veterinary Medicine, Veterinärplatz 1, 1210, Vienna, Austria.

Christoph W Sensen (CW)

Institute of Computational Biotechnology, Graz University of Technology, Petersgasse 14/V, 8010, Graz, Styria, Austria; CNA Diagnostics GmbH, Parkring 18, 8074, Grambach, Styria, Austria; BioTechMed Graz, Mozartgasse 12/II, 8010, Graz, Styria, Austria. Electronic address: csensen@tugraz.at.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH